{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:21:54Z","timestamp":1793816514681,"version":"4.6.1"},"reference-count":157,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Kunming Medical University Joint Special Project - Key Project","award":["202401AY070001-023"],"award-info":[{"award-number":["202401AY070001-023"]}]},{"name":"Joint Special Funds for the Department of Science and Technology of Yunnan Province-Kunming Medical University","award":["202001AY070001-266"],"award-info":[{"award-number":["202001AY070001-266"]}]},{"name":"Kunming Health Science and Technology Personnel Training Project-Leading talents in medical science and technology","award":["2023-SW(Leader)-03"],"award-info":[{"award-number":["2023-SW(Leader)-03"]}]},{"name":"Kunming Health Science and Technology Personnel Training Project-Medical science and technology leader","award":["2023-SW (Lead)-15"],"award-info":[{"award-number":["2023-SW (Lead)-15"]}]},{"name":"Yunnan Provincial Education Department Scientific Research Fund","award":["2024J0285"],"award-info":[{"award-number":["2024J0285"]}]},{"name":"Xingdian Talent Support Program","award":["410103197910153712"],"award-info":[{"award-number":["410103197910153712"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06851-2","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T09:20:08Z","timestamp":1754558408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["G protein-coupled receptors: pivotal hubs in gastric cancer malignancy\u2014from multidimensional crosstalk to precision therapeutics"],"prefix":"10.1186","volume":"23","author":[{"given":"Rong","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xirui","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyao","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5293-4612","authenticated-orcid":false,"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"issue":"1","key":"6851_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A. Cancer statistics, 2025. CA Cancer J Clin. 2025;75(1):10\u201345. https:\/\/doi.org\/10.3322\/caac.21871.","journal-title":"CA Cancer J Clin"},{"key":"6851_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1532605","author":"X He","year":"2025","unstructured":"He X, Guan XY, Li Y. Clinical significance of the tumor microenvironment on immune tolerance in gastric cancer. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1532605.","journal-title":"Front Immunol"},{"key":"6851_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1558091","author":"Y He","year":"2025","unstructured":"He Y, Hong Q, Chen S, Zhou J, Qiu S. Reprogramming tumor-associated macrophages in gastric cancer: a pathway to enhanced immunotherapy. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1558091.","journal-title":"Front Immunol"},{"issue":"6","key":"6851_CR4","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.4240\/wjgs.v16.i6.1660","volume":"16","author":"SF Nie","year":"2024","unstructured":"Nie SF, Wang CY, Li L, Yang C, Zhu ZM, Fei JD. Tumor recurrence and survival prognosis in patients with advanced gastric cancer after radical resection with radiotherapy and chemotherapy. World J Gastrointest Surg. 2024;16(6):1660. https:\/\/doi.org\/10.4240\/wjgs.v16.i6.1660.","journal-title":"World J Gastrointest Surg"},{"issue":"1","key":"6851_CR5","doi-asserted-by":"publisher","first-page":"192","DOI":"10.5230\/jgc.2025.25.e3","volume":"25","author":"HS Lee","year":"2025","unstructured":"Lee HS. Spatial and Temporal tumor heterogeneity in gastric cancer: discordance of predictive biomarkers. J Gastric Cancer. 2025;25(1):192\u2013209. https:\/\/doi.org\/10.5230\/jgc.2025.25.e3.","journal-title":"J Gastric Cancer"},{"issue":"6480","key":"6851_CR6","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1126\/science.aaz0326","volume":"367","author":"CM Suomivuori","year":"2020","unstructured":"Suomivuori CM, Latorraca NR, Wingler LM, Eismann S, King MC, Kleinhenz ALW, et al. Molecular mechanism of biased signaling in a prototypical G protein-coupled receptor. Science. 2020;367(6480):881. https:\/\/doi.org\/10.1126\/science.aaz0326.","journal-title":"Science"},{"issue":"2","key":"6851_CR7","doi-asserted-by":"publisher","first-page":"103390biom15020","DOI":"10.3390\/biom15020291","volume":"15","author":"YY Cho","year":"2025","unstructured":"Cho YY, Kim S, Kim P, Jo MJ, Park SE, Choi Y, et al. G-Protein-Coupled receptor (GPCR) signaling and Pharmacology in metabolism: physiology, mechanisms, and therapeutic potential. Biomolecules. 2025;15(2):103390biom15020291.","journal-title":"Biomolecules"},{"key":"6851_CR8","doi-asserted-by":"crossref","unstructured":"Hashem S, Dougha A, Tuff\u00e9ry P. Ligand-Induced Biased Activation of GPCRs: Recent Advances and New Directions from In Silico Approaches. Molecules. 2025;30(5)10.3390\/molecules30051047.","DOI":"10.3390\/molecules30051047"},{"key":"6851_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108786","author":"Y Ma","year":"2025","unstructured":"Ma Y, Patterson B, Zhu L. Biased signaling in gpcrs: structural insights and implications for drug development. Pharmacol Ther. 2025. https:\/\/doi.org\/10.1016\/j.pharmthera.2024.108786.","journal-title":"Pharmacol Ther"},{"key":"6851_CR10","doi-asserted-by":"crossref","unstructured":"Yan H, Zhang JL, Leung KT, Lo KW, Yu J, To KF et al. An Update of G-Protein-Coupled Receptor Signaling and Its Deregulation in Gastric Carcinogenesis. Cancers (Basel). 2023;15(3)10.3390\/cancers15030736.","DOI":"10.3390\/cancers15030736"},{"issue":"16","key":"6851_CR11","doi-asserted-by":"publisher","first-page":"4849","DOI":"10.7150\/jca.55719","volume":"12","author":"W Zhou","year":"2021","unstructured":"Zhou W, Ouyang J, Li J, Liu F, An T, Cheng L, et al. MRPS17 promotes invasion and metastasis through PI3K\/AKT signal pathway and could be potential prognostic marker for gastric cancer. J Cancer. 2021;12(16):4849\u201361. https:\/\/doi.org\/10.7150\/jca.55719.","journal-title":"J Cancer"},{"key":"6851_CR12","doi-asserted-by":"publisher","unstructured":"Wang B, Wang L, Lu Y, Liang W, Gao Y, Xi H, et al. GRSF1 promotes tumorigenesis and EMT-mediated metastasis through PI3K\/AKT pathway in gastric cancer. Biochem Biophys Res Commun. 2021;55561. https:\/\/doi.org\/10.1016\/j.bbrc.2021.03.121.","DOI":"10.1016\/j.bbrc.2021.03.121"},{"issue":"12","key":"6851_CR13","doi-asserted-by":"publisher","first-page":"509","DOI":"10.5414\/cp204250","volume":"60","author":"M Ye","year":"2022","unstructured":"Ye M, Xiu LJ, Ji QQ, Zhang YC, Sun YW, Zhao Y, et al. Research progress in targeted therapies for gastric cancer. Int J Clin Pharmacol Ther. 2022;60(12):509\u201314. https:\/\/doi.org\/10.5414\/cp204250.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"6851_CR14","doi-asserted-by":"crossref","unstructured":"Lau DK, Collin JP, Mariadason JM. Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer. Biomedicines. 2024;12(5)10.3390\/biomedicines12051117.","DOI":"10.3390\/biomedicines12051117"},{"issue":"6489","key":"6851_CR15","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.aaz8995","volume":"368","author":"J Yu","year":"2020","unstructured":"Yu J, Gimenez LE, Hernandez CC, Wu Y, Wein AH, Han GW, et al. Determination of the melanocortin-4 receptor structure identifies Ca(2+) as a cofactor for ligand binding. Science. 2020;368(6489):428\u201333. https:\/\/doi.org\/10.1126\/science.aaz8995.","journal-title":"Science"},{"issue":"7840","key":"6851_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-020-2994-1","volume":"589","author":"V Velazhahan","year":"2021","unstructured":"Velazhahan V, Ma N, P\u00e1ndy-Szekeres G, Kooistra AJ, Lee Y, Gloriam DE, et al. Structure of the class D GPCR Ste2 dimer coupled to two G proteins. Nature. 2021;589(7840):148\u201353. https:\/\/doi.org\/10.1038\/s41586-020-2994-1.","journal-title":"Nature"},{"key":"6851_CR17","doi-asserted-by":"crossref","unstructured":"Lopez-Balastegui M, Stepniewski TM, Kogut-G\u00fcnthel MM, Di Pizio A, Rosenkilde MM, Mao J et al. Relevance of G protein-coupled receptor (GPCR) dynamics for receptor activation, signalling bias and allosteric modulation. Br J Pharmacol. 2024;10.1111\/bph.16495.","DOI":"10.1111\/bph.16495"},{"issue":"2","key":"6851_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.beem.2018.01.004","volume":"32","author":"D Calebiro","year":"2018","unstructured":"Calebiro D, Godbole A. Internalization of G-protein-coupled receptors: implication in receptor function, physiology and diseases. Best Pract Res Clin Endocrinol Metab. 2018;32(2):83\u201391. https:\/\/doi.org\/10.1016\/j.beem.2018.01.004.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"6851_CR19","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41574-024-00957-1","volume":"20","author":"J Duan","year":"2024","unstructured":"Duan J, He XH, Li SJ, Xu HE. Cryo-electron microscopy for GPCR research and drug discovery in endocrinology and metabolism. Nat Rev Endocrinol. 2024;20(6):349\u201365. https:\/\/doi.org\/10.1038\/s41574-024-00957-1.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"6851_CR20","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/jcp.25615","volume":"232","author":"V May","year":"2017","unstructured":"May V, Parsons RL. G Protein-Coupled receptor endosomal signaling and regulation of neuronal excitability and stress responses: signaling options and lessons from the PAC1 receptor. J Cell Physiol. 2017;232(4):698\u2013706. https:\/\/doi.org\/10.1002\/jcp.25615.","journal-title":"J Cell Physiol"},{"key":"6851_CR21","doi-asserted-by":"crossref","unstructured":"Fouillen A, Bous J, Granier S, Mouillac B, Sounier R. Bringing GPCR Structural Biology to Medical Applications: Insights from Both V2 Vasopressin and Mu-Opioid Receptors. Membranes (Basel). 2023;13(6)10.3390\/membranes13060606.","DOI":"10.3390\/membranes13060606"},{"key":"6851_CR22","doi-asserted-by":"publisher","unstructured":"Cheng L, Xia F, Li Z, Shen C, Yang Z, Hou H, et al. Structure, function and drug discovery of GPCR signaling. Mol Biomed. 2023;4(1). https:\/\/doi.org\/10.1186\/s43556-023-00156-w.","DOI":"10.1186\/s43556-023-00156-w"},{"issue":"4","key":"6851_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1124\/molpharm.124.000974","volume":"106","author":"D Salom","year":"2024","unstructured":"Salom D, Wu A, Liu CC, Palczewski K. The impact of nanobodies on G Protein-Coupled receptor structural biology and their potential as therapeutic agents. Mol Pharmacol. 2024;106(4):155\u201363. https:\/\/doi.org\/10.1124\/molpharm.124.000974.","journal-title":"Mol Pharmacol"},{"key":"6851_CR24","doi-asserted-by":"publisher","unstructured":"Wingler LM, Lefkowitz RJ. Conformational basis of G Protein-Coupled receptor signaling versatility. Trends Cell Biol. 2020;30(9)736\u2009\u2212\u200947. https:\/\/doi.org\/10.1016\/j.tcb.2020.06.002.","DOI":"10.1016\/j.tcb.2020.06.002"},{"issue":"8","key":"6851_CR25","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1111\/febs.15841","volume":"288","author":"D Hilger","year":"2021","unstructured":"Hilger D. The role of structural dynamics in GPCR-mediated signaling. Febs J. 2021;288(8):2461\u201389. https:\/\/doi.org\/10.1111\/febs.15841.","journal-title":"Febs J"},{"key":"6851_CR26","doi-asserted-by":"crossref","unstructured":"Hilger D, Kumar KK, Hu H, Pedersen MF, O\u2019Brien ES, Giehm L et al. Structural insights into differences in G protein activation by family A and family B GPCRs. Science. 2020;369(6503)10.1126\/science.aba3373.","DOI":"10.1126\/science.aba3373"},{"key":"6851_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmgm.2023.108434","author":"GL Szwabowski","year":"2023","unstructured":"Szwabowski GL, Baker DL, Parrill AL. Application of computational methods for class A GPCR ligand discovery. J Mol Graph Model. 2023. https:\/\/doi.org\/10.1016\/j.jmgm.2023.108434.","journal-title":"J Mol Graph Model"},{"issue":"6","key":"6851_CR28","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jsps.2021.04.015","volume":"29","author":"K Alhosaini","year":"2021","unstructured":"Alhosaini K, Azhar A, Alonazi A, Al-Zoghaibi F, GPCRs. The most promiscuous druggable receptor of the mankind. Saudi Pharm J. 2021;29(6):539\u201351. https:\/\/doi.org\/10.1016\/j.jsps.2021.04.015.","journal-title":"Saudi Pharm J"},{"key":"6851_CR29","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pharmtox-010919-023301","author":"D Wootten","year":"2020","unstructured":"Wootten D, Miller LJ. Structural basis for allosteric modulation of class B G Protein-Coupled receptors. Annu Rev Pharmacol Toxicol. 2020. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010919-023301. 6089\u2013\u2009107.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"6851_CR30","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.tibs.2020.07.008","volume":"45","author":"A Ellaithy","year":"2020","unstructured":"Ellaithy A, Gonzalez-Maeso J, Logothetis DA, Levitz J. Structural and biophysical mechanisms of class C G Protein-Coupled receptor function. Trends Biochem Sci. 2020;45(12):1049\u201364. https:\/\/doi.org\/10.1016\/j.tibs.2020.07.008.","journal-title":"Trends Biochem Sci"},{"key":"6851_CR31","doi-asserted-by":"publisher","unstructured":"Turku A, Schihada H, Kozielewicz P, Bowin CF, Schulte G. Residue 6.43 defines receptor function in class F GPCRs. Nat Commun. 2021;12(1). https:\/\/doi.org\/10.1038\/s41467-021-24004-z.","DOI":"10.1038\/s41467-021-24004-z"},{"issue":"6","key":"6851_CR32","doi-asserted-by":"publisher","first-page":"2622","DOI":"10.3390\/cimb44060179","volume":"44","author":"ZB Sun","year":"2022","unstructured":"Sun ZB, Yu SF, Wang CL, Wang L. cAMP signalling pathway in biocontrol Fungi. Curr Issues Mol Biol. 2022;44(6):2622. https:\/\/doi.org\/10.3390\/cimb44060179.","journal-title":"Curr Issues Mol Biol"},{"key":"6851_CR33","doi-asserted-by":"crossref","unstructured":"Conflitti P, Lyman E, Sansom MSP, Hildebrand PW, Guti\u00e9rrez-de-Ter\u00e1n H, Carloni P et al. Functional dynamics of G protein-coupled receptors reveal new routes for drug discovery. Nat Rev Drug Discov. 2025;10.1038\/s41573-024-01083-3.","DOI":"10.1038\/s41573-024-01083-3"},{"key":"6851_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2022.146564","author":"Y Yang","year":"2022","unstructured":"Yang Y, Chen M, Qiu Y, Li X, Huang Y, Zhang W. The apelin\/aplnr system modulates tumor immune response by reshaping the tumor microenvironment. Gene. 2022. https:\/\/doi.org\/10.1016\/j.gene.2022.146564.","journal-title":"Gene"},{"key":"6851_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2021.114419","author":"M Lov\u00e1szi","year":"2021","unstructured":"Lov\u00e1szi M, Branco Haas C, Antonioli L, Pacher P, Hask\u00f3 G. The role of P2Y receptors in regulating immunity and metabolism. Biochem Pharmacol. 2021. https:\/\/doi.org\/10.1016\/j.bcp.2021.114419.","journal-title":"Biochem Pharmacol"},{"key":"6851_CR36","doi-asserted-by":"crossref","unstructured":"Ma N, Xu E, Luo Q, Song G. Rac1: A Regulator of Cell Migration and a Potential Target for Cancer Therapy. Molecules. 2023;28(7)10.3390\/molecules28072976.","DOI":"10.3390\/molecules28072976"},{"key":"6851_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1482308","author":"J Wang","year":"2025","unstructured":"Wang J, Ding N, Chen C, Gu S, Liu J, Wang Y, et al. Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1482308.","journal-title":"Front Immunol"},{"key":"6851_CR38","doi-asserted-by":"publisher","unstructured":"Li L, An Z, Lin C, Xu Q, Tang C. An update on regulation and function of G protein-coupled receptors in cancer: A promising strategy for cancer therapy. Biochim Biophys Acta Rev Cancer. 2025;1880(2). https:\/\/doi.org\/10.1016\/j.bbcan.2025.189266.","DOI":"10.1016\/j.bbcan.2025.189266"},{"issue":"1","key":"6851_CR39","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.4110\/in.2025.25.e15","volume":"25","author":"SG Park","year":"2025","unstructured":"Park SG, Lee JY, Seo H, Hwang SS, Lee CK, Lee GR. Modulation of immune responses by metabolic reprogramming: the key role of immunometabolism. Immune Netw. 2025;25(1):e15. https:\/\/doi.org\/10.4110\/in.2025.25.e15.","journal-title":"Immune Netw"},{"issue":"6","key":"6851_CR40","doi-asserted-by":"publisher","first-page":"103390ijms26062","DOI":"10.3390\/ijms26062553","volume":"26","author":"Y Wang","year":"2025","unstructured":"Wang Y, Anesi JC, Panicker IS, Cook D, Bista P, Fang Y, et al. Neuroimmune interactions and their role in immune cell trafficking in cardiovascular diseases and Cancer. Int J Mol Sci. 2025;26(6):103390ijms26062553.","journal-title":"Int J Mol Sci"},{"key":"6851_CR41","doi-asserted-by":"publisher","unstructured":"Yu JH, Choi MG, Lee NY, Kwon A, Lee E, Koo JH. Hepatocyte GPCR signaling regulates IRF3 to control hepatic stellate cell transdifferentiation. Cell Commun Signal. 2024;22(1). https:\/\/doi.org\/10.1186\/s12964-023-01416-6.","DOI":"10.1186\/s12964-023-01416-6"},{"key":"6851_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.609532","author":"A Ben-Shmuel","year":"2021","unstructured":"Ben-Shmuel A, Sabag B, Biber G, Barda-Saad M. The role of the cytoskeleton in regulating the natural killer cell immune response in health and disease: from signaling dynamics to function. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.609532.","journal-title":"Front Cell Dev Biol"},{"key":"6851_CR43","doi-asserted-by":"publisher","unstructured":"Li L, Tang J, Cao B, Xu Q, Xu S, Lin C, et al. GPR137 inactivates Hippo signaling to promote gastric cancer cell malignancy. Biol Direct. 2024;19(1). https:\/\/doi.org\/10.1186\/s13062-023-00449-8.","DOI":"10.1186\/s13062-023-00449-8"},{"key":"6851_CR44","doi-asserted-by":"publisher","unstructured":"Gu X, Shen H, Xiang Z, Li X, Zhang Y, Zhang R, et al. Exploring the correlation between GPR176, a potential target gene of gastric cancer, and immune cell infiltration. Pharmgenomics Pers Med. 2023;16519\u201335. https:\/\/doi.org\/10.2147\/pgpm.S411199.","DOI":"10.2147\/pgpm.S411199"},{"key":"6851_CR45","doi-asserted-by":"publisher","DOI":"10.1155\/2023\/7123568","author":"L Ni","year":"2023","unstructured":"Ni L, Chen S, Liu J, Li H, Zhao H, Zheng C, et al. GPR176 is a biomarker for predicting prognosis and immune infiltration in stomach adenocarcinoma. Mediators Inflamm. 2023. https:\/\/doi.org\/10.1155\/2023\/7123568.","journal-title":"Mediators Inflamm"},{"issue":"1","key":"6851_CR46","doi-asserted-by":"publisher","first-page":"9360","DOI":"10.1038\/s41598-023-36586-3","volume":"13","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Gu X, Zhu F, Li Y, Huang Y, Ju S. High expression of GPR176 predicts poor prognosis of gastric cancer patients and promotes the proliferation, migration, and invasion of gastric cancer cells. Sci Rep. 2023;13(1):9360. https:\/\/doi.org\/10.1038\/s41598-023-36586-3.","journal-title":"Sci Rep"},{"issue":"6","key":"6851_CR47","doi-asserted-by":"publisher","first-page":"572","DOI":"10.21147\/j.issn.1000-9604.2017.06.12","volume":"29","author":"C Guo","year":"2017","unstructured":"Guo C, Hou J, Ao S, Deng X, Lyu G. HOXC10 up-regulation promotes gastric cancer cell proliferation and metastasis through MAPK pathway. Chin J Cancer Res. 2017;29(6):572\u201380. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2017.06.12.","journal-title":"Chin J Cancer Res"},{"issue":"3","key":"6851_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.prp.2018.12.004","volume":"215","author":"X Zhu","year":"2019","unstructured":"Zhu X, Huang G, Jin P. Clinicopathological and prognostic significance of aberrant G protein-couple receptor 110 (GPR110) expression in gastric cancer. Pathol Res Pract. 2019;215(3):539\u201345. https:\/\/doi.org\/10.1016\/j.prp.2018.12.004.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"6851_CR49","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/carcin\/bgac018","volume":"43","author":"Z Gao","year":"2022","unstructured":"Gao Z, Long Y, Wu Y, Pu Y, Xue F. LncRNA LINC02253 activates KRT18\/MAPK\/ERK pathway by mediating N6-methyladenosine modification of KRT18 mRNA in gastric cancer. Carcinogenesis. 2022;43(5):419\u201329. https:\/\/doi.org\/10.1093\/carcin\/bgac018.","journal-title":"Carcinogenesis"},{"key":"6851_CR50","doi-asserted-by":"publisher","unstructured":"Shu C, Wang C, Chen S, Huang X, Cui J, Li W, et al. ERR-activated GPR35 promotes immune infiltration level of macrophages in gastric cancer tissues. Cell Death Discov. 2022;8(1). https:\/\/doi.org\/10.1038\/s41420-022-01238-4.","DOI":"10.1038\/s41420-022-01238-4"},{"issue":"4","key":"6851_CR51","doi-asserted-by":"publisher","first-page":"545","DOI":"10.4103\/0366-6999.151114","volume":"128","author":"ZT Jin","year":"2015","unstructured":"Jin ZT, Li K, Li M, Ren ZG, Wang FS, Zhu JY, et al. G-protein coupled receptor 34 knockdown impairs the proliferation and migration of HGC-27 gastric cancer cells in vitro. Chin Med J (Engl). 2015;128(4):545\u20139. https:\/\/doi.org\/10.4103\/0366-6999.151114.","journal-title":"Chin Med J (Engl)"},{"issue":"5","key":"6851_CR52","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5483\/bmbrep.2018.51.5.046","volume":"51","author":"J Seo","year":"2018","unstructured":"Seo J, Kee HJ, Choi HJ, Lee JE, Park SY, Lee SH, et al. Inhibition of Wntless\/GPR177 suppresses gastric tumorigenesis. BMB Rep. 2018;51(5):255\u201360. https:\/\/doi.org\/10.5483\/bmbrep.2018.51.5.046.","journal-title":"BMB Rep"},{"issue":"1","key":"6851_CR53","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.canlet.2012.07.031","volume":"326","author":"L Cheng","year":"2012","unstructured":"Cheng L, Yang S, Yang Y, Zhang W, Xiao H, Gao H, et al. Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker. Cancer Lett. 2012;326(1):105\u201313. https:\/\/doi.org\/10.1016\/j.canlet.2012.07.031.","journal-title":"Cancer Lett"},{"key":"6851_CR54","doi-asserted-by":"publisher","unstructured":"Wegner MS, Gruber L, Sch\u00f6mel N, Trautmann S, Brachtendorf S, Fuhrmann D, et al. GPER1 influences cellular homeostasis and cytostatic drug resistance via influencing long chain ceramide synthesis in breast cancer cells. Int J Biochem Cell Biol. 2019;11295\u2013106. https:\/\/doi.org\/10.1016\/j.biocel.2019.05.002.","DOI":"10.1016\/j.biocel.2019.05.002"},{"issue":"3","key":"6851_CR55","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.bbrc.2019.10.122","volume":"524","author":"Q Wang","year":"2020","unstructured":"Wang Q, Shi M, Sun S, Zhou Q, Ding L, Jiang C, et al. CLEC5A promotes the proliferation of gastric cancer cells by activating the PI3K\/AKT\/mTOR pathway. Biochem Biophys Res Commun. 2020;524(3):656\u201362. https:\/\/doi.org\/10.1016\/j.bbrc.2019.10.122.","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"6851_CR56","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s11626-021-00627-w","volume":"57","author":"J Zhang","year":"2021","unstructured":"Zhang J, Lv W, Liu Y, Fu W, Chen B, Ma Q, et al. Nucleoporin 37 promotes the cell proliferation, migration, and invasion of gastric cancer through activating the PI3K\/AKT\/mTOR signaling pathway. Vitro Cell Dev Biol Anim. 2021;57(10):987\u201397. https:\/\/doi.org\/10.1007\/s11626-021-00627-w.","journal-title":"Vitro Cell Dev Biol Anim"},{"issue":"2","key":"6851_CR57","doi-asserted-by":"publisher","first-page":"713","DOI":"10.26355\/eurrev_202301_31074","volume":"27","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhang HM, Guo YR, Li LL, Zhang GZ. Role of sphingosine-1-phosphate receptors in the tumor microenvironment: prospects for cancer immunotherapy. Eur Rev Med Pharmacol Sci. 2023;27(2):713\u201327. https:\/\/doi.org\/10.26355\/eurrev_202301_31074.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"6851_CR58","doi-asserted-by":"publisher","unstructured":"Calebiro D, Koszegi Z. The subcellular dynamics of GPCR signaling. Mol Cell Endocrinol. 2019;48324. https:\/\/doi.org\/10.1016\/j.mce.2018.12.020.","DOI":"10.1016\/j.mce.2018.12.020"},{"key":"6851_CR59","doi-asserted-by":"publisher","unstructured":"Yuan L, Barbash S, Kongsamut S, Eishingdrelo A, Sakmar TP, Eishingdrelo H. 14-3-3 signal adaptor and scaffold proteins mediate GPCR trafficking. Sci Rep. 2019;9(1). https:\/\/doi.org\/10.1038\/s41598-019-47478-w.","DOI":"10.1038\/s41598-019-47478-w"},{"issue":"9","key":"6851_CR60","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/s41589-018-0115-3","volume":"14","author":"F Yang","year":"2018","unstructured":"Yang F, Xiao P, Qu CX, Liu Q, Wang LY, Liu ZX, et al. Allosteric mechanisms underlie GPCR signaling to SH3-domain proteins through arrestin. Nat Chem Biol. 2018;14(9):876\u201386. https:\/\/doi.org\/10.1038\/s41589-018-0115-3.","journal-title":"Nat Chem Biol"},{"issue":"6","key":"6851_CR61","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1053\/j.gastro.2019.01.266","volume":"156","author":"M Canals","year":"2019","unstructured":"Canals M, Poole DP, Veldhuis NA, Schmidt BL, Bunnett NW. G-Protein-Coupled receptors are dynamic regulators of digestion and targets for digestive diseases. Gastroenterology. 2019;156(6):1600\u201316. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.266.","journal-title":"Gastroenterology"},{"issue":"3","key":"6851_CR62","doi-asserted-by":"publisher","first-page":"e23449","DOI":"10.1096\/fj.202301172RRRR","volume":"38","author":"T Wu","year":"2024","unstructured":"Wu T, Ding K, Wang C, Lin G, Xie C, Chen X, et al. G-protein-coupled Estrogen receptor 1 promotes peritoneal metastasis of gastric cancer through nicotinamide adenine dinucleotide kinase 1-mediated redox modulation. Faseb J. 2024;38(3):e23449. https:\/\/doi.org\/10.1096\/fj.202301172RRRR.","journal-title":"Faseb J"},{"key":"6851_CR63","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.591239","author":"E Xu","year":"2020","unstructured":"Xu E, Xia X, Jiang C, Li Z, Yang Z, Zheng C, et al. GPER1 Silencing suppresses the proliferation, migration, and invasion of gastric Cancer cells by inhibiting PI3K\/AKT-Mediated EMT. Front Cell Dev Biol. 2020. https:\/\/doi.org\/10.3389\/fcell.2020.591239.","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"6851_CR64","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41388-021-02069-w","volume":"41","author":"SAK Rasheed","year":"2022","unstructured":"Rasheed SAK, Subramanyan LV, Lim WK, Udayappan UK, Wang M, Casey PJ. The emerging roles of G\u03b112\/13 proteins on the hallmarks of cancer in solid tumors. Oncogene. 2022;41(2):147\u201358. https:\/\/doi.org\/10.1038\/s41388-021-02069-w.","journal-title":"Oncogene"},{"key":"6851_CR65","doi-asserted-by":"publisher","unstructured":"Rourke JL, Dranse HJ, Sinal CJ. CMKLR1 and GPR1 mediate chemerin signaling through the rhoa\/rock pathway. Mol Cell Endocrinol. 2015;41736\u201351. https:\/\/doi.org\/10.1016\/j.mce.2015.09.002.","DOI":"10.1016\/j.mce.2015.09.002"},{"key":"6851_CR66","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/7957018","author":"X Sun","year":"2024","unstructured":"Sun X, Guo Y. Chemerin enhances migration and invasion of OC cells via CMKLR1\/RhoA\/ROCK-Mediated EMT. Int J Endocrinol. 2024. https:\/\/doi.org\/10.1155\/2024\/7957018.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"6851_CR67","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/fjc.0000000000000482","volume":"70","author":"PY Jean-Charles","year":"2017","unstructured":"Jean-Charles PY, Kaur S, Shenoy SK. G Protein-Coupled receptor signaling through \u03b2-Arrestin-Dependent mechanisms. J Cardiovasc Pharmacol. 2017;70(3):142\u201358. https:\/\/doi.org\/10.1097\/fjc.0000000000000482.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"6851_CR68","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/jim-2018-000934","volume":"67","author":"Y Jia","year":"2019","unstructured":"Jia Y, Li Z, Cheng X, Wu X, Pang F, Shi J, et al. Depletion of death-associated protein-3 induces chemoresistance in gastric cancer cells through the \u03b2-catenin\/LGR5\/Bcl-2 axis. J Investig Med. 2019;67(5):856\u201361. https:\/\/doi.org\/10.1136\/jim-2018-000934.","journal-title":"J Investig Med"},{"key":"6851_CR69","doi-asserted-by":"crossref","unstructured":"Cassier E, Gallay N, Bourquard T, Claeysen S, Bockaert J, Cr\u00e9pieux P et al. Phosphorylation of \u03b2-arrestin2 at Thr(383) by MEK underlies \u03b2-arrestin-dependent activation of Erk1\/2 by GPCRs. Elife. 2017;610.7554\/eLife.23777.","DOI":"10.7554\/eLife.23777.029"},{"key":"6851_CR70","doi-asserted-by":"publisher","unstructured":"Ko MJ, Chiang T, Mukadam AA, Mulia GE, Gutridge AM, Lin A, et al. \u03b2-Arrestin-dependent ERK signaling reduces anxiety-like and conditioned fear-related behaviors in mice. Sci Signal. 2021;14(694). https:\/\/doi.org\/10.1126\/scisignal.aba0245.","DOI":"10.1126\/scisignal.aba0245"},{"issue":"1","key":"6851_CR71","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.canlet.2015.02.043","volume":"361","author":"NB Hao","year":"2015","unstructured":"Hao NB, Tang B, Wang GZ, Xie R, Hu CJ, Wang SM, et al. Hepatocyte growth factor (HGF) upregulates heparanase expression via the PI3K\/Akt\/NF-\u03baB signaling pathway for gastric cancer metastasis. Cancer Lett. 2015;361(1):57\u201366. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.043.","journal-title":"Cancer Lett"},{"key":"6851_CR72","doi-asserted-by":"publisher","unstructured":"Li O, Zhao C, Zhang J, Li FN, Yang ZY, Liu SL, et al. UBAP2L promotes gastric cancer metastasis by activating NF-\u03baB through PI3K\/AKT pathway. Cell Death Discov. 2022;8(1). https:\/\/doi.org\/10.1038\/s41420-022-00916-7.","DOI":"10.1038\/s41420-022-00916-7"},{"key":"6851_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-11-71","author":"SG Crone","year":"2012","unstructured":"Crone SG, Jacobsen A, Federspiel B, Bardram L, Krogh A, Lund AH, et al. microRNA-146a inhibits G protein-coupled receptor-mediated activation of NF-\u03baB by targeting CARD10 and COPS8 in gastric cancer. Mol Cancer. 2012. https:\/\/doi.org\/10.1186\/1476-4598-11-71.","journal-title":"Mol Cancer"},{"issue":"5","key":"6851_CR74","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/biof.1773","volume":"47","author":"Y Guo","year":"2021","unstructured":"Guo Y, Zhou K, Zhuang X, Li J, Shen X. CDCA7-regulated inflammatory mechanism through TLR4\/NF-\u03baB signaling pathway in stomach adenocarcinoma. BioFactors. 2021;47(5):865\u201378. https:\/\/doi.org\/10.1002\/biof.1773.","journal-title":"BioFactors"},{"issue":"3","key":"6851_CR75","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.7150\/jca.103093","volume":"16","author":"S Chen","year":"2025","unstructured":"Chen S, He J, Gao H, Gao X, Dai L, Chen J, et al. ADAMTS7 enhances gastric Cancer growth and metastasis by triggering the NF-\u03baB signaling pathway. J Cancer. 2025;16(3):1008\u201319. https:\/\/doi.org\/10.7150\/jca.103093.","journal-title":"J Cancer"},{"issue":"4","key":"6851_CR76","doi-asserted-by":"publisher","first-page":"103390toxins904","DOI":"10.3390\/toxins9040119","volume":"9","author":"O Sokolova","year":"2017","unstructured":"Sokolova O, Naumann M. NF-\u03baB signaling in gastric Cancer. Toxins (Basel). 2017;9(4):103390toxins9040119.","journal-title":"Toxins (Basel)"},{"key":"6851_CR77","doi-asserted-by":"publisher","unstructured":"Zhao Z, Xiong S, Gao J, Zhang Y, Guo E, Huang Y. C3(+) cancer-associated fibroblasts promote tumor growth and therapeutic resistance in gastric cancer via activation of the NF-\u03baB signaling pathway. J Transl Med. 2024;22(1). https:\/\/doi.org\/10.1186\/s12967-024-05939-5.","DOI":"10.1186\/s12967-024-05939-5"},{"issue":"9","key":"6851_CR78","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1111\/cas.16258","volume":"115","author":"H Yu","year":"2024","unstructured":"Yu H, Kohno S, Voon DC, Hussein NH, Zhang Y, Nakayama J, et al. RECK\/GPR124-driven WNT signaling in pancreatic and gastric cancer cells. Cancer Sci. 2024;115(9):3013\u201325. https:\/\/doi.org\/10.1111\/cas.16258.","journal-title":"Cancer Sci"},{"issue":"5","key":"6851_CR79","first-page":"2354","volume":"8","author":"J Yan","year":"2016","unstructured":"Yan J, Liu T, Zhou X, Dang Y, Yin C, Zhang G. FZD6, targeted by miR-21, represses gastric cancer cell proliferation and migration via activating non-canonical Wnt pathway. Am J Transl Res. 2016;8(5):2354\u201364.","journal-title":"Am J Transl Res"},{"issue":"3","key":"6851_CR80","doi-asserted-by":"publisher","first-page":"280","DOI":"10.7150\/ijbs.23756","volume":"14","author":"G Li","year":"2018","unstructured":"Li G, Su Q, Liu H, Wang D, Zhang W, Lu Z, et al. Frizzled7 promotes Epithelial-to-mesenchymal transition and stemness via activating canonical Wnt\/\u03b2-catenin pathway in gastric Cancer. Int J Biol Sci. 2018;14(3):280\u201393. https:\/\/doi.org\/10.7150\/ijbs.23756.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"6851_CR81","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.3748\/wjg.v22.i3.1279","volume":"22","author":"W Kang","year":"2016","unstructured":"Kang W, Cheng AS, Yu J, To KF. Emerging role of Hippo pathway in gastric and other Gastrointestinal cancers. World J Gastroenterol. 2016;22(3):1279\u201388. https:\/\/doi.org\/10.3748\/wjg.v22.i3.1279.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"6851_CR82","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/cam4.1085","volume":"6","author":"LJ Xue","year":"2017","unstructured":"Xue LJ, Mao XB, Ren LL, Chu XY. Inhibition of CXCL12\/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma. Cancer Med. 2017;6(6):1424\u201336. https:\/\/doi.org\/10.1002\/cam4.1085.","journal-title":"Cancer Med"},{"issue":"10","key":"6851_CR83","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.7150\/jca.49707","volume":"12","author":"Y Qin","year":"2021","unstructured":"Qin Y, Wang F, Ni H, Liu Y, Yin Y, Zhou X, et al. Cancer-associated fibroblasts in gastric cancer affect malignant progression via the CXCL12-CXCR4 axis. J Cancer. 2021;12(10):3011. https:\/\/doi.org\/10.7150\/jca.49707.","journal-title":"J Cancer"},{"key":"6851_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2024.104901","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang F, Liu Z, Li M, Wu G, Li H. P2RX1-blocked neutrophils induce CD8(+) T cell dysfunction and affect the immune escape of gastric cancer cells. Cell Immunol. 2025. https:\/\/doi.org\/10.1016\/j.cellimm.2024.104901.","journal-title":"Cell Immunol"},{"issue":"1","key":"6851_CR85","doi-asserted-by":"publisher","first-page":"e2130","DOI":"10.1002\/biof.2130","volume":"51","author":"J Tang","year":"2025","unstructured":"Tang J, Wei W, Xu Y, Chen K, Miao Y, Fan W, et al. CXC chemokine receptor 4 - mediated immune modulation and tumor microenvironment heterogeneity in gastric cancer: utilizing multi-omics approaches to identify potential therapeutic targets. BioFactors. 2025;51(1):e2130. https:\/\/doi.org\/10.1002\/biof.2130.","journal-title":"BioFactors"},{"key":"6851_CR86","doi-asserted-by":"publisher","unstructured":"Wen F, Lu X, Huang W, Chen X, Ruan S, Gu S, et al. Characteristics of immunophenotypes and immunological in tumor microenvironment and analysis of immune implication of CXCR4 in gastric cancer. Sci Rep. 2022;12(1). https:\/\/doi.org\/10.1038\/s41598-022-08622-1.","DOI":"10.1038\/s41598-022-08622-1"},{"issue":"3","key":"6851_CR87","doi-asserted-by":"publisher","first-page":"392","DOI":"10.17305\/bjbms.2022.8317","volume":"23","author":"H Shen","year":"2023","unstructured":"Shen H, Gu X, Li X, Xiang Z, Zhang R, Shi F, et al. C5aR1 shapes a non-inflammatory tumor microenvironment and mediates immune evasion in gastric cancer. Biomol Biomed. 2023;23(3):392\u2013404. https:\/\/doi.org\/10.17305\/bjbms.2022.8317.","journal-title":"Biomol Biomed"},{"key":"6851_CR88","doi-asserted-by":"crossref","unstructured":"Pawluczuk E, \u0141ukaszewicz-Zaj\u0105c M, Gryko M, Kulczy\u0144ska-Przybik A, Mroczko B. Serum CXCL8 and Its Specific Receptor (CXCR2) in Gastric Cancer. Cancers (Basel). 2021;13(20)10.3390\/cancers13205186.","DOI":"10.3390\/cancers13205186"},{"issue":"8","key":"6851_CR89","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/cbin.10794","volume":"41","author":"Q Zhang","year":"2017","unstructured":"Zhang Q, Xu F, Shi Y, Chen YW, Wang HP, Yu X, et al. C-X-C motif chemokine receptor 4 promotes tumor angiogenesis in gastric cancer via activation of JAK2\/STAT3. Cell Biol Int. 2017;41(8):854\u201362. https:\/\/doi.org\/10.1002\/cbin.10794.","journal-title":"Cell Biol Int"},{"key":"6851_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.654504","author":"Y Gu","year":"2021","unstructured":"Gu Y, Gu W, Xie R, Chen Z, Xu T, Fei Z. Role of CXCR4 as a prognostic biomarker associated with the tumor immune microenvironment in gastric Cancer. Front Cell Dev Biol. 2021. https:\/\/doi.org\/10.3389\/fcell.2021.654504.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"6851_CR91","doi-asserted-by":"publisher","first-page":"103390ijms24010","DOI":"10.3390\/ijms24010615","volume":"24","author":"Y Li","year":"2022","unstructured":"Li Y, Liu A, Liu S, Yan L, Yuan Y, Xu Q. Involvement of CXCL17 and GPR35 in gastric Cancer initiation and progression. Int J Mol Sci. 2022;24(1):103390ijms24010615.","journal-title":"Int J Mol Sci"},{"key":"6851_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.asjsur.2024.07.355","author":"L Wang","year":"2024","unstructured":"Wang L, Xu Y, Jiang L, Liu J. The elevated expression of ADGRL4 indicates poor prognosis in gastric cancer. Asian J Surg. 2024. https:\/\/doi.org\/10.1016\/j.asjsur.2024.07.355.","journal-title":"Asian J Surg"},{"issue":"4","key":"6851_CR93","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3892\/br.2016.606","volume":"4","author":"F Tas","year":"2016","unstructured":"Tas F, Karabulut S, Tastekin D, Duranyildiz D. Clinical significance of serum protease-activated receptor-1 levels in gastric cancer patients. Biomed Rep. 2016;4(4):489\u201392. https:\/\/doi.org\/10.3892\/br.2016.606.","journal-title":"Biomed Rep"},{"issue":"2","key":"6851_CR94","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.bbrc.2008.10.018","volume":"377","author":"Y Tanaka","year":"2008","unstructured":"Tanaka Y, Sekiguchi F, Hong H, Kawabata A. PAR2 triggers IL-8 release via MEK\/ERK and PI3-kinase\/Akt pathways in GI epithelial cells. Biochem Biophys Res Commun. 2008;377(2):622. https:\/\/doi.org\/10.1016\/j.bbrc.2008.10.018.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"6851_CR95","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/bcpt.13873","volume":"133","author":"O Cevhero\u011flu","year":"2023","unstructured":"Cevhero\u011flu O, Demir N, Kesici MS, \u00d6z\u00e7ubuk\u00e7u S, Son \u00c7D. Downstream signalling of the disease-associated mutations on GPR56\/ADGRG1. Basic Clin Pharmacol Toxicol. 2023;133(4):331\u201341. https:\/\/doi.org\/10.1111\/bcpt.13873.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6851_CR96","doi-asserted-by":"crossref","unstructured":"Sak K. The path of GPR87: from a P2Y-like receptor to its role in cancer progression. Naunyn Schmiedebergs Arch Pharmacol. 2024;10.1007\/s00210-024-03684-6.","DOI":"10.1007\/s00210-024-03684-6"},{"issue":"3","key":"6851_CR97","doi-asserted-by":"publisher","first-page":"101172jci158705","DOI":"10.1172\/JCI158705","volume":"133","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Chen Y, Shi Y, Wu L, Tan Y, Li T, et al., et al. FAM117B promotes gastric cancer growth and drug resistance by targeting the KEAP1\/NRF2 signaling pathway. J Clin Invest. 2023;133(3):101172jci158705.","journal-title":"J Clin Invest"},{"key":"6851_CR98","doi-asserted-by":"publisher","unstructured":"Wang X, He S, Gu Y, Wang Q, Chu X, Jin M, et al. Fatty acid receptor GPR120 promotes breast cancer chemoresistance by upregulating ABC transporters expression and fatty acid synthesis. EBioMedicine. 2019;40251\u201362. https:\/\/doi.org\/10.1016\/j.ebiom.2018.12.037.","DOI":"10.1016\/j.ebiom.2018.12.037"},{"issue":"3","key":"6851_CR99","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.metabol.2013.11.003","volume":"63","author":"X Shen","year":"2014","unstructured":"Shen X, Yang L, Yan S, Wei W, Liang L, Zheng H, et al. The effect of FFAR1 on pioglitazone-mediated Attenuation of palmitic acid-induced oxidative stress and apoptosis in \u03b2TC6 cells. Metabolism. 2014;63(3):335\u201351. https:\/\/doi.org\/10.1016\/j.metabol.2013.11.003.","journal-title":"Metabolism"},{"key":"6851_CR100","doi-asserted-by":"crossref","unstructured":"Reyna-Jeldes M, De la Fuente-Ortega E, Cerda D, Vel\u00e1zquez-Miranda E, Pinto K, V\u00e1zquez-Cuevas FG et al. Purinergic P2Y2 and P2X4 Receptors Are Involved in the Epithelial-Mesenchymal Transition and Metastatic Potential of Gastric Cancer Derived Cell Lines. Pharmaceutics. 2021;13(8)10.3390\/pharmaceutics13081234.","DOI":"10.3390\/pharmaceutics13081234"},{"issue":"1","key":"6851_CR101","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/carcin\/bgac095","volume":"44","author":"CR Dong","year":"2023","unstructured":"Dong CR, Hu DX, Liu SC, Luo HL, Zhang WJ. AKT\/GSK-3beta\/VEGF signaling is involved in P2RY2 activation-induced the proliferation and metastasis of gastric cancer. Carcinogenesis. 2023;44(1):65\u201379. https:\/\/doi.org\/10.1093\/carcin\/bgac095.","journal-title":"Carcinogenesis"},{"issue":"48","key":"6851_CR102","doi-asserted-by":"publisher","first-page":"e28059","DOI":"10.1097\/md.0000000000028059","volume":"100","author":"T Zheng","year":"2021","unstructured":"Zheng T, Sun M, Liu L, Lan Y, Wang L, Lin F. GPR116 overexpression correlates with poor prognosis in gastric cancer. Med (Baltim). 2021;100(48):e28059. https:\/\/doi.org\/10.1097\/md.0000000000028059.","journal-title":"Med (Baltim)"},{"issue":"8","key":"6851_CR103","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1038\/bjc.2014.112","volume":"110","author":"HQ Xi","year":"2014","unstructured":"Xi HQ, Cai AZ, Wu XS, Cui JX, Shen WS, Bian SB, et al. Leucine-rich repeat-containing G-protein-coupled receptor 5 is associated with invasion, metastasis, and could be a potential therapeutic target in human gastric cancer. Br J Cancer. 2014;110(8):2011\u201320. https:\/\/doi.org\/10.1038\/bjc.2014.112.","journal-title":"Br J Cancer"},{"issue":"10","key":"6851_CR104","doi-asserted-by":"publisher","first-page":"2267","DOI":"10.1093\/annonc\/mdq739","volume":"22","author":"WL Cheng","year":"2011","unstructured":"Cheng WL, Wang CS, Huang YH, Tsai MM, Liang Y, Lin KH. Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann Oncol. 2011;22(10):2267. https:\/\/doi.org\/10.1093\/annonc\/mdq739.","journal-title":"Ann Oncol"},{"issue":"6","key":"6851_CR105","doi-asserted-by":"publisher","first-page":"591","DOI":"10.14348\/molcells.2018.0025","volume":"41","author":"H Akter","year":"2018","unstructured":"Akter H, Yoon JH, Yoo YS, Kang MJ. Validation of neurotensin receptor 1 as a therapeutic target for gastric Cancer. Mol Cells. 2018;41(6):591\u2013602. https:\/\/doi.org\/10.14348\/molcells.2018.0025.","journal-title":"Mol Cells"},{"issue":"9","key":"6851_CR106","doi-asserted-by":"publisher","first-page":"10651","DOI":"10.3390\/cimb46090632","volume":"46","author":"S Bademler","year":"2024","unstructured":"Bademler S, K\u0131l\u0131\u00e7 B, \u00dc\u00e7\u00fcnc\u00fc M, Zirtiloglu A, \u0130lhan B. The role of biomarkers in the early diagnosis of gastric cancer: A study on CCR5, CCL5, PDGF, and EphA7. Curr Issues Mol Biol. 2024;46(9):10651\u201361. https:\/\/doi.org\/10.3390\/cimb46090632.","journal-title":"Curr Issues Mol Biol"},{"key":"6851_CR107","doi-asserted-by":"publisher","unstructured":"Xu D, Liu X, Ke S, Guo Y, Zhu C, Cao H. CCL19\/CCR7 drives regulatory T cell migration and indicates poor prognosis in gastric cancer. BMC Cancer. 2023;23(1). https:\/\/doi.org\/10.1186\/s12885-023-10882-7.","DOI":"10.1186\/s12885-023-10882-7"},{"key":"6851_CR108","doi-asserted-by":"publisher","unstructured":"Natsuki S, Yoshii M, Tanaka H, Mori T, Deguchi S, Miki Y, et al. Involvement of CX3CR1(+) cells appearing in the abdominal cavity in the immunosuppressive environment immediately after gastric cancer surgery. World J Surg Oncol. 2024;22(1). https:\/\/doi.org\/10.1186\/s12957-024-03353-1.","DOI":"10.1186\/s12957-024-03353-1"},{"key":"6851_CR109","doi-asserted-by":"publisher","DOI":"10.1038\/srep42089","author":"D Shimizu","year":"2017","unstructured":"Shimizu D, Kanda M, Tanaka H, Kobayashi D, Tanaka C, Hayashi M, et al. GPR155 serves as a predictive biomarker for hematogenous metastasis in patients with gastric Cancer. Sci Rep. 2017. https:\/\/doi.org\/10.1038\/srep42089.","journal-title":"Sci Rep"},{"issue":"4","key":"6851_CR110","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000452977","volume":"34","author":"S Nambara","year":"2017","unstructured":"Nambara S, Iguchi T, Oki E, Tan P, Maehara Y, Mimori K. Overexpression of CXCR7 is a novel prognostic Indicator in gastric Cancer. Dig Surg. 2017;34(4):312\u20138. https:\/\/doi.org\/10.1159\/000452977.","journal-title":"Dig Surg"},{"key":"6851_CR111","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.702615","author":"S Xue","year":"2021","unstructured":"Xue S, Ma M, Bei S, Li F, Wu C, Li H, et al. Identification and validation of the immune regulator CXCR4 as a novel promising target for gastric Cancer. Front Immunol. 2021. https:\/\/doi.org\/10.3389\/fimmu.2021.702615.","journal-title":"Front Immunol"},{"issue":"23","key":"6851_CR112","doi-asserted-by":"publisher","first-page":"103390ijms24231","DOI":"10.3390\/ijms242316986","volume":"24","author":"Q Wu","year":"2023","unstructured":"Wu Q, Wang P, Peng Q, Kang Z, Deng Y, Li J, et al. Adhesion G Protein-Coupled receptor G2 promotes hepatocellular carcinoma progression and serves as a Neutrophil-Related prognostic biomarker. Int J Mol Sci. 2023;24(23):103390ijms242316986.","journal-title":"Int J Mol Sci"},{"key":"6851_CR113","doi-asserted-by":"crossref","unstructured":"Franco Machado J, Silva RD, Melo R. JD GC. Less Exploited GPCRs in Precision Medicine: Targets for Molecular Imaging and Theranostics. Molecules. 2018;24(1)10.3390\/molecules24010049.","DOI":"10.3390\/molecules24010049"},{"issue":"12","key":"6851_CR114","doi-asserted-by":"publisher","first-page":"e570","DOI":"10.1097\/rlu.0000000000003727","volume":"46","author":"Y Kou","year":"2021","unstructured":"Kou Y, Yao Z, Cheng Z. Al18F-NOTA-FAPI-04 outperforms 18F-FDG PET\/CT in identifying the primary lesion and rare metastases from gastric Cancer. Clin Nucl Med. 2021;46(12):e570\u2013e. https:\/\/doi.org\/10.1097\/rlu.0000000000003727.","journal-title":"Clin Nucl Med"},{"key":"6851_CR115","doi-asserted-by":"publisher","unstructured":"Li H, Qiao Z, Xiao X, Cao X, Li Z, Liu M, et al. G protein-coupled receptors: A golden key to the treasure-trove of neurodegenerative diseases. Clin Nutr. 2025;46155\u201368. https:\/\/doi.org\/10.1016\/j.clnu.2025.01.032.","DOI":"10.1016\/j.clnu.2025.01.032"},{"issue":"27","key":"6851_CR116","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.2217\/fon-2018-0418","volume":"14","author":"H Wei","year":"2018","unstructured":"Wei H, Li Y, Du Y, Ma J. KCND2 upregulation might be an independent indicator of poor survival in gastric cancer. Future Oncol. 2018;14(27):2811\u201320. https:\/\/doi.org\/10.2217\/fon-2018-0418.","journal-title":"Future Oncol"},{"issue":"6","key":"6851_CR117","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1007\/s10120-019-00974-4","volume":"22","author":"JY Kim","year":"2019","unstructured":"Kim JY, Kim WG, Kwon CH, Park DY. Differences in immune contextures among different molecular subtypes of gastric cancer and their prognostic impact. Gastric Cancer. 2019;22(6):1164. https:\/\/doi.org\/10.1007\/s10120-019-00974-4.","journal-title":"Gastric Cancer"},{"key":"6851_CR118","doi-asserted-by":"publisher","unstructured":"Chen H, Jing C, Shang L, Zhu X, Zhang R, Liu Y, et al. Molecular characterization and clinical relevance of metabolic signature subtypes in gastric cancer. Cell Rep. 2024;43(7). https:\/\/doi.org\/10.1016\/j.celrep.2024.114424.","DOI":"10.1016\/j.celrep.2024.114424"},{"key":"6851_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.labinv.2025.104101","author":"Z Ye","year":"2025","unstructured":"Ye Z, Wu X, Wei Z, Sun Q, Wang Y, Li T, et al. Microsatellite stable gastric cancer can be classified into two molecular subtypes with different immunotherapy response and prognosis based on gene sequencing and computational pathology. Lab Invest. 2025. https:\/\/doi.org\/10.1016\/j.labinv.2025.104101.","journal-title":"Lab Invest"},{"issue":"12","key":"6851_CR120","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.tips.2020.10.001","volume":"41","author":"AC Cornwell","year":"2020","unstructured":"Cornwell AC, Feigin ME. Unintended effects of GPCR-Targeted drugs on the Cancer phenotype. Trends Pharmacol Sci. 2020;41(12):1006\u201322. https:\/\/doi.org\/10.1016\/j.tips.2020.10.001.","journal-title":"Trends Pharmacol Sci"},{"key":"6851_CR121","doi-asserted-by":"publisher","unstructured":"Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876(1). https:\/\/doi.org\/10.1016\/j.bbcan.2021.188549.","DOI":"10.1016\/j.bbcan.2021.188549"},{"issue":"10","key":"6851_CR122","doi-asserted-by":"publisher","first-page":"103390jcm121033","DOI":"10.3390\/jcm12103391","volume":"12","author":"S Ariga","year":"2023","unstructured":"Ariga S. History and future of HER2-Targeted therapy for advanced gastric Cancer. J Clin Med. 2023;12(10):103390jcm12103391.","journal-title":"J Clin Med"},{"issue":"7","key":"6851_CR123","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1016\/j.cellsig.2014.03.029","volume":"26","author":"J Gatfield","year":"2014","unstructured":"Gatfield J, Monnier L, Studer R, Bolli MH, Steiner B, Nayler O. Sphingosine-1-phosphate (S1P) displays sustained S1P1 receptor agonism and signaling through S1P lyase-dependent receptor recycling. Cell Signal. 2014;26(7):1576\u201388. https:\/\/doi.org\/10.1016\/j.cellsig.2014.03.029.","journal-title":"Cell Signal"},{"issue":"8 Suppl 3","key":"6851_CR124","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1212\/WNL.0b013e31820d5ec1","volume":"76","author":"T Hla","year":"2011","unstructured":"Hla T, Brinkmann V. Sphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulation. Neurology. 2011;76(8 Suppl 3):S3\u20138. https:\/\/doi.org\/10.1212\/WNL.0b013e31820d5ec1.","journal-title":"Neurology"},{"key":"6851_CR125","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2024.1158852","author":"Y Yang","year":"2024","unstructured":"Yang Y, Xing S, Luo X, Guan L, Lu Y, Wang Y, et al. Unraveling the prognostic significance of RGS gene family in gastric cancer and the potential implication of RGS4 in regulating tumor-infiltrating fibroblast. Front Mol Biosci. 2024. https:\/\/doi.org\/10.3389\/fmolb.2024.1158852.","journal-title":"Front Mol Biosci"},{"key":"6851_CR126","doi-asserted-by":"publisher","unstructured":"Chen PY, Wang PY, Liu B, Jia YP, Zhang ZX, Liu X, et al. RGS4 promotes the progression of gastric cancer through the focal adhesion kinase\/phosphatidyl-inositol-3-kinase\/protein kinase B pathway and epithelial-mesenchymal transition. World J Gastroenterol. 2025;31(2). https:\/\/doi.org\/10.3748\/wjg.v31.i2.100898.","DOI":"10.3748\/wjg.v31.i2.100898"},{"key":"6851_CR127","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167711","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Jia Z, Cao D, Zhong Y, Wu Y, Fu Y, et al. RGS1 can serve as a long-term prognostic marker in gastric cancer by promoting the infiltration and polarization of macrophages. Biochim Biophys Acta Mol Basis Dis. 2025. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167711.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"22","key":"6851_CR128","doi-asserted-by":"publisher","first-page":"16626","DOI":"10.1021\/acs.jmedchem.1c01219","volume":"64","author":"Y Dong","year":"2021","unstructured":"Dong Y, Fu R, Chen J, Zhang K, Ji M, Wang M, et al. Discovery of benzocyclic sulfone derivatives as potent CXCR2 antagonists for Cancer immunotherapy. J Med Chem. 2021;64(22):16626\u201340. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01219.","journal-title":"J Med Chem"},{"issue":"4","key":"6851_CR129","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/jleuko\/qiad150","volume":"115","author":"Z Tan","year":"2024","unstructured":"Tan Z, Chiu MS, Yue M, Kwok HY, Tse MH, Wen Y, et al. Enhancing the efficacy of vaccinia-based oncolytic virotherapy by inhibiting CXCR2-mediated MDSC trafficking. J Leukoc Biol. 2024;115(4):633\u201346. https:\/\/doi.org\/10.1093\/jleuko\/qiad150.","journal-title":"J Leukoc Biol"},{"issue":"24","key":"6851_CR130","doi-asserted-by":"publisher","first-page":"103390cancers13","DOI":"10.3390\/cancers13246293","volume":"13","author":"K Bullock","year":"2021","unstructured":"Bullock K, Richmond A. Suppressing MDSC recruitment to the tumor microenvironment by antagonizing CXCR2 to enhance the efficacy of immunotherapy. Cancers (Basel). 2021;13(24):103390cancers13246293.","journal-title":"Cancers (Basel)"},{"issue":"22","key":"6851_CR131","doi-asserted-by":"publisher","first-page":"12435","DOI":"10.1073\/pnas.1920310117","volume":"117","author":"J Kim","year":"2020","unstructured":"Kim J, Grotegut CA, Wisler JW, Mao L, Rosenberg PB, Rockman HA, et al. The \u03b2-arrestin-biased \u03b2-adrenergic receptor blocker carvedilol enhances skeletal muscle contractility. Proc Natl Acad Sci U S A. 2020;117(22):12435\u201343. https:\/\/doi.org\/10.1073\/pnas.1920310117.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"6851_CR132","doi-asserted-by":"publisher","first-page":"4558","DOI":"10.1073\/pnas.1815515116","volume":"116","author":"IX Chen","year":"2019","unstructured":"Chen IX, Chauhan VP, Posada J, Ng MR, Wu MW, Adstamongkonkul P, et al. Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019;116(10):4558\u2013. https:\/\/doi.org\/10.1073\/pnas.1815515116.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6851_CR133","doi-asserted-by":"publisher","unstructured":"Pervaiz A, Ansari S, Berger MR, Adwan H. CCR5 blockage by Maraviroc induces cytotoxic and apoptotic effects in colorectal cancer cells. Med Oncol. 2015;32(5). https:\/\/doi.org\/10.1007\/s12032-015-0607-x.","DOI":"10.1007\/s12032-015-0607-x"},{"key":"6851_CR134","doi-asserted-by":"crossref","unstructured":"Alka K, Oyeniyi JF, Mohammad G, Zhao Y, Marcus S, Chinnaiyan P. The RAGE Inhibitor TTP488 (Azeliragon) Demonstrates Anti-Tumor Activity and Enhances the Efficacy of Radiation Therapy in Pancreatic Cancer Cell Lines. Cancers (Basel). 2024;17(1)10.3390\/cancers17010017.","DOI":"10.3390\/cancers17010017"},{"key":"6851_CR135","doi-asserted-by":"publisher","unstructured":"Rolland WB, Lekic T, Krafft PR, Hasegawa Y, Altay O, Hartman R, et al. Fingolimod reduces cerebral lymphocyte infiltration in experimental models of rodent intracerebral hemorrhage. Exp Neurol. 2013;24145. https:\/\/doi.org\/10.1016\/j.expneurol.2012.12.009.","DOI":"10.1016\/j.expneurol.2012.12.009"},{"issue":"18","key":"6851_CR136","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1158\/1078-0432.Ccr-16-2748","volume":"23","author":"AF Schott","year":"2017","unstructured":"Schott AF, Goldstein LJ, Cristofanilli M, Ruffini PA, McCanna S, Reuben JM, et al. Phase Ib pilot study to evaluate reparixin in combination with weekly Paclitaxel in patients with HER-2-Negative metastatic breast Cancer. Clin Cancer Res. 2017;23(18):5358\u201365. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-2748.","journal-title":"Clin Cancer Res"},{"key":"6851_CR137","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1535703","author":"P Hu","year":"2025","unstructured":"Hu P, Liu W, Huang J, Su Y, Jiang H, Wu Q, et al. Navarixin alleviates cardiac remodeling after myocardial infarction by decreasing neutrophil infiltration and the inflammatory response. Front Pharmacol. 2025. https:\/\/doi.org\/10.3389\/fphar.2025.1535703.","journal-title":"Front Pharmacol"},{"issue":"1","key":"6851_CR138","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2013.09.012","volume":"70","author":"AL Chang","year":"2014","unstructured":"Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60\u20139. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.012.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"6851_CR139","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1097\/cad.0000000000001640","volume":"35","author":"Z Zhu","year":"2024","unstructured":"Zhu Z, Nie X, Deng L, Ding J, Chen J, Zhu J, et al. Regulation of cervical cancer via G15-mediated Inhibition of G protein-coupled Estrogen receptor. Anticancer Drugs. 2024;35(9):817\u201329. https:\/\/doi.org\/10.1097\/cad.0000000000001640.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"6851_CR140","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1158\/1535-7163.Mct-14-0850","volume":"14","author":"SB Peng","year":"2015","unstructured":"Peng SB, Zhang X, Paul D, Kays LM, Gough W, Stewart J, et al. Identification of LY2510924, a novel Cyclic peptide CXCR4 antagonist that exhibits antitumor activities in solid tumor and breast cancer metastatic models. Mol Cancer Ther. 2015;14(2):480\u201390. https:\/\/doi.org\/10.1158\/1535-7163.Mct-14-0850.","journal-title":"Mol Cancer Ther"},{"issue":"22","key":"6851_CR141","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.Ccr-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, et al. Phase ia\/b, Open-Label, multicenter study of AZD4635 (an adenosine A2A receptor Antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin Cancer Res. 2022;28(22):4871\u201384. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-0612.","journal-title":"Clin Cancer Res"},{"key":"6851_CR142","doi-asserted-by":"publisher","unstructured":"Perrot I, Michaud HA, Giraudon-Paoli M, Augier S, Docquier A, Gros L, et al. Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination Cancer therapies. Cell Rep. 2019;27(8). https:\/\/doi.org\/10.1016\/j.celrep.2019.04.091.","DOI":"10.1016\/j.celrep.2019.04.091"},{"issue":"1","key":"6851_CR143","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/s40425-019-0706-x","volume":"7","author":"M Bilusic","year":"2019","unstructured":"Bilusic M, Heery CR, Collins JM, Donahue RN, Palena C, Madan RA, et al. Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J Immunother Cancer. 2019;7(1):240. https:\/\/doi.org\/10.1186\/s40425-019-0706-x.","journal-title":"J Immunother Cancer"},{"key":"6851_CR144","doi-asserted-by":"publisher","unstructured":"Jeong Y, Yoon SY, Jung SP, Nam SJ, Lee JE, Kim S. Inhibition of IL-8\/CXCR2 signaling axis prevents tumor growth and metastasis in triple negative breast cancer cells. Pharmacology. 2025;1\u201317. https:\/\/doi.org\/10.1159\/000545659.","DOI":"10.1159\/000545659"},{"issue":"4","key":"6851_CR145","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s11302-019-09678-x","volume":"15","author":"SD Bellefeuille","year":"2019","unstructured":"Bellefeuille SD, Molle CM, Gendron FP. Reviewing the role of P2Y receptors in specific Gastrointestinal cancers. Purinergic Signal. 2019;15(4):451\u201363. https:\/\/doi.org\/10.1007\/s11302-019-09678-x.","journal-title":"Purinergic Signal"},{"key":"6851_CR146","doi-asserted-by":"crossref","unstructured":"Bar-Shavit R, Maoz M, Kancharla A, Nag JK, Agranovich D, Grisaru-Granovsky S et al. G Protein-Coupled Receptors in Cancer. Int J Mol Sci. 2016;17(8)10.3390\/ijms17081320.","DOI":"10.3390\/ijms17081320"},{"issue":"5","key":"6851_CR147","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s10585-024-10292-4","volume":"41","author":"LM Mehner","year":"2024","unstructured":"Mehner LM, Munoz-Sagredo L, Sonnentag SJ, Treffert SM, Orian-Rousseau V. Targeting CD44 and other pleiotropic co-receptors as a means for broad Inhibition of tumor growth and metastasis. Clin Exp Metastasis. 2024;41(5):599\u2013611. https:\/\/doi.org\/10.1007\/s10585-024-10292-4.","journal-title":"Clin Exp Metastasis"},{"key":"6851_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2019.111853","author":"J Che","year":"2020","unstructured":"Che J, Song R, Chen B, Dong X. Targeting CXCR1\/2: the medicinal potential as cancer immunotherapy agents, antagonists research highlights and challenges ahead. Eur J Med Chem. 2020. https:\/\/doi.org\/10.1016\/j.ejmech.2019.111853.","journal-title":"Eur J Med Chem"},{"key":"6851_CR149","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00431","author":"PA Insel","year":"2018","unstructured":"Insel PA, Sriram K, Wiley SZ, Wilderman A, Katakia T, McCann T, et al. GPCRomics: GPCR expression in Cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Front Pharmacol. 2018. https:\/\/doi.org\/10.3389\/fphar.2018.00431.","journal-title":"Front Pharmacol"},{"key":"6851_CR150","doi-asserted-by":"publisher","first-page":"14e23829","DOI":"10.1096\/fj.202400458R","volume":"38","author":"GH Qiu","year":"2024","unstructured":"Qiu GH, Yu B, Ma M. G protein-coupled receptor-mediated signaling of Immunomodulation in tumor progression. Faseb J. 2024;38:14e23829. https:\/\/doi.org\/10.1096\/fj.202400458R.","journal-title":"Faseb J"},{"key":"6851_CR151","doi-asserted-by":"crossref","unstructured":"Suteau V, Munier M, Ben Boubaker R, Wery M, Henrion D, Rodien P et al. Identification of Dysregulated Expression of G Protein Coupled Receptors in Endocrine Tumors by Bioinformatics Analysis: Potential Drug Targets? Cells. 2022;11(4)10.3390\/cells11040703.","DOI":"10.3390\/cells11040703"},{"key":"6851_CR152","doi-asserted-by":"publisher","unstructured":"Yuan W, Shi X, Lee LTO. RNA therapeutics in targeting G protein-coupled receptors: recent advances and challenges. Mol Ther Nucleic Acids. 2024;35(2). https:\/\/doi.org\/10.1016\/j.omtn.2024.102195.","DOI":"10.1016\/j.omtn.2024.102195"},{"key":"6851_CR153","doi-asserted-by":"crossref","unstructured":"Lorente JS, Sokolov AV, Ferguson G, Schi\u00f6th HB, Hauser AS, Gloriam DE. GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2025;10.1038\/s41573-025-01139-y.","DOI":"10.1038\/s41573-025-01139-y"},{"issue":"9","key":"6851_CR154","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1016\/j.drudis.2020.07.004","volume":"25","author":"H Ma","year":"2020","unstructured":"Ma H, Huang B, Zhang Y. Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. Drug Discov Today. 2020;25(9):1682\u201392. https:\/\/doi.org\/10.1016\/j.drudis.2020.07.004.","journal-title":"Drug Discov Today"},{"issue":"14","key":"6851_CR155","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1111\/bph.16052","volume":"181","author":"R Pokhrel","year":"2024","unstructured":"Pokhrel R, Morgan AL, Robinson HR, Stone MJ, Foster SR. Unravelling G protein-coupled receptor signalling networks using global phosphoproteomics. Br J Pharmacol. 2024;181(14):2359\u201370. https:\/\/doi.org\/10.1111\/bph.16052.","journal-title":"Br J Pharmacol"},{"key":"6851_CR156","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00114","author":"A Bagnato","year":"2019","unstructured":"Bagnato A, Rosan\u00f2 L. New routes in GPCR\/\u03b2-Arrestin-Driven signaling in Cancer progression and metastasis. Front Pharmacol. 2019. https:\/\/doi.org\/10.3389\/fphar.2019.00114.","journal-title":"Front Pharmacol"},{"issue":"7835","key":"6851_CR157","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/s41586-020-2888-2","volume":"587","author":"M Marti-Solano","year":"2020","unstructured":"Marti-Solano M, Crilly SE, Malinverni D, Munk C, Harris M, Pearce A, et al. Combinatorial expression of GPCR isoforms affects signalling and drug responses. Nature. 2020;587(7835):650. https:\/\/doi.org\/10.1038\/s41586-020-2888-2.","journal-title":"Nature"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06851-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06851-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06851-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T15:10:07Z","timestamp":1757344207000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06851-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":157,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6851"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06851-2","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable (N\/A).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"879"}}